AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-22. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Most refrigerator-freezers—except for manual defrost models or cheaper units—use what appears to be two thermostats. Only the refrigerator compartment is properly temperature controlled. When the refrigerator gets too warm, the thermostat starts the cooling process and a fan circulates the air around the freezer. During this time, the refrigerator also gets colder. The freezer control knob only controls the amount of air that flows into the refrigerator via a damper system. Changing the refrigerator temperature will inadvertently change the freezer temperature in the opposite direction. Changing the freezer temperature will have no effect on the refrigerator temperature. The freezer control may also be adjusted to compensate for any refrigerator adjustment. This means the refrigerator may become too warm. However, because only enough air is diverted to the refrigerator compartment, the freezer usually re-acquires the set temperature quickly, unless the door is opened. When a door is opened, either in the refrigerator or the freezer, the fan in some units stops immediately to prevent excessive frost build up on the freezer's evaporator coil, because this coil is cooling two areas. When the freezer reaches temperature, the unit cycles off, no matter what the refrigerator temperature is. Modern computerized refrigerators do not use the damper system. The computer manages fan speed for both compartments, although air is still blown from the freezer.
==== L ==== Lavashak is a Persian fruit leather made of plums, apricots, or pomegranates. Li hing mui – is salty dried plum. In most parts of China, it is called huamei. It was made popular in Hawaii by Yee Sheong, who in early 1900s, had begun importing li hing mui and various other preserved fruits i.e. crack seed snacks from China to Hawaii. The red powder, called li hing powder, consists of ground-up plum skin that has previously been pickled in a combination of licorice, aspartame, food coloring, salt, and sugar.
Since travellers exiting Hyder into Stewart, British Columbia, are subject to Canadian border controls, it is theoretically possible for someone to accidentally enter Hyder from Canada without their travel documents and then face difficulties, as both the U.S. and Canada would subject them to border controls that require travel documents. At the same time, however, the northern road connecting Hyder to the uninhabited mountain regions of British Columbia has neither American nor Canadian border controls, meaning that tourists from Canada proceeding northwards from Hyder are required to complete Canadian immigration formalities when they return to Stewart, despite never having cleared American immigration.
Sources: en.wikipedia.org
=== 17 May === Russia claimed to have destroyed more than 100 air and naval drones over its western regions and in the Black Sea. Explosions were reported at petroleum facilities in Novorossiysk, while two people were reported killed in a drone strike in Belgorod Oblast. The Russian-installed Governor of Sevastopol, Mikhail Razvozhayev, said that the attack caused power outages in the city. Four people were killed and 31 were wounded in a Russian airstrike in Kharkiv. Two people were killed in a separate attack in Vovchansk, while one person was killed in Lyptsi. Police accused Russian soldiers in the town of using up to 40 civilian prisoners as human shields. The regional prosecutor's office also began a criminal proceeding on Russian soldiers allegedly executing a person in a wheelchair. Zelenskyy signed a bill into law permitting individuals convicted of minor offenses to serve in the Ukrainian military, as well as another bill that increases fines for draft dodgers fivefold. Zelenskyy reported the situation in Kharkiv had been "controlled" but not "stabilized". He also reported Ukraine has "about 25 percent" of the air defences needed to counter future Russian attacks, needing 120 to 130 F-16s or other advanced aircraft to achieve air "parity" with Russia.
=== Properties === Detrital zircons usually retain similar properties as their parent igneous rocks, such as age, rough size and mineral chemistry. However, the composition of detrital zircons is not entirely controlled by the crystallization of the zircon mineral. In fact, many of them are modified by later processes in the sedimentary cycle. Depending on the degree of physical sorting, mechanical abrasion and dissolution, a detrital zircon grain may lose some of its inherent features and gain some over-printed properties like rounded shape and smaller size. On a larger scale, two or more tribes of detrital zircons from different origins may deposit within the same sedimentary basin. This gives rise to a natural complexity of associating detrital zircon populations and their sources. Zircon is a strong tool for uranium-lead age determination because of its inherent properties:
Martin Fleischmann of the University of Southampton and Stanley Pons of the University of Utah hypothesized that the high compression ratio and mobility of deuterium that could be achieved within palladium metal using electrolysis might result in nuclear fusion. To investigate, they conducted electrolysis experiments using a palladium cathode and heavy water within a calorimeter, an insulated vessel designed to measure process heat. Current was applied continuously for many weeks, with the heavy water being renewed at intervals. Some deuterium was thought to be accumulating within the cathode, but most was allowed to bubble out of the cell, joining oxygen produced at the anode. For most of the time, the power input to the cell was equal to the calculated power leaving the cell within measurement accuracy, and the cell temperature was stable at around 30 °C. But then, at some point (in some of the experiments), the temperature rose suddenly to about 50 °C without changes in the input power. These high temperature phases would last for two days or more and would repeat several times in any given experiment once they had occurred. The calculated power leaving the cell was significantly higher than the input power during these high temperature phases. Eventually the high temperature phases would no longer occur within a particular cell. In 1988, Fleischmann and Pons applied to the United States Department of Energy for funding towards a larger series of experiments. Up to this point they had been funding their experiments using a small device built with $100,000 out-of-pocket.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.